Protalix BioTherapeutics – Consensus Indicates Potential 183.2% Upside

Broker Ratings

Protalix BioTherapeutics found using ticker (PLX) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 15 and 11 with a mean TP of 13. Given that the stocks previous close was at 4.59 this would indicate that there is a potential upside of 183.2%. The day 50 moving average is 3.81 and the 200 day MA is 3.65. The company has a market capitalisation of $153m. Find out more information at: http://www.protalix.com

Protalix BioTherapeutics, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp

AIM All Share Index